Multiomics Solutions
Pharmaceutical & Biotechnology Companies
Together, Let's Improve the Odds of Success in Discovery and Development
At Signios Bio, we partner with pharma and biotech companies for complete solutions to improve drug discovery and development and promote precision medicine. We provide the tools and expertise to work with complex biological data, find new targets for therapies, and speed up the development of effective treatments.
Why choose Signios Bio as your research partner?
We help you identify targets & biomarkers by using advanced multiomics technologies and powerful, AI-enhanced bioinformatics, all backed by the experience and expertise of our world class scientists.
Accelerate the production of validated recombinant antibodies with our high-throughput antibody discovery services. By leveraging advanced single-cell sequencing within a comprehensive, end-to-end workflow, we significantly reduce timelines so you can progress from target antigen to antibodies in as little as four months.
As part of MedGenome, we have access to real-world evidence (RWE) from global research networks across the US, Europe, Asia, Africa, Middle East, and Latin America. This access enables us to work with our partners to uncover insights that can lead to bio markers and drug targets, ensuring that precision medicine is inclusive and effective for all.
Complete Solutions to Help Your Development Work
DNA Sequencing Options with Short or Long Reads
Whole Genome Sequencing
Find disease-causing mutations, pharmacogenomic markers, and genetic differences between populations
Exome Sequencing
Discover new drug targets and biomarkers by analyzing protein-coding regions
Targeted Sequencing
Develop companion diagnostics and monitor how patients are responding to treatment with detailed analysis of specific genomic regions
RNA Sequencing Options with Short or Long Reads
RNA Sequencing
Learn about disease processes, find therapeutic targets, and discover biomarkers through gene expression
Single-Cell RNA Sequencing
Find new drug targets and mechanisms of resistance with gene expression in individual cells
Spatial RNA Sequencing
Analyze how drugs work and resistance develops within the tumor environment
Epigenomic Sequencing Options with Short or Long Reads
ChIP-Seq or ATAC-Seq
Explain how drugs work and resistance develops by studying chromatin modifications and protein-DNA interactions
Methylome Sequencing
Identify epigenetic biomarkers and learn how DNA methylation affects drug response
Antibody Development Solutions
HiTMab - Monoclonal Antibody Discovery
Generate specific antibodies to accelerate therapeutic and diagnostic development
Real-world evidence (RWE) from global research networks across the US, Europe, Asia, Africa, Middle East, and Latin America
Real World Evidence
We provide access to real-world evidence (RWE) from richly diverse research programs across the US, Europe, Asia, Africa, Middle East, and Latin America.
Real Solutions for Real-World Applications
Signios Bio offers specialized multiomics solutions designed to investigate the complexities of oncology, immunology, neurology, and rare & infectious diseases. By combining multiple modalities with our advanced bioinformatics, we are able to offer customized multiomics solutions for your research.
TME Signal
Identifies distinct cell populations and gene regulatory networks driving tumor evolution via transcriptomics at single-cell and spatial resolution
TCR/BCR Profile Signal
Investigates clonal expansion of antigen specific T and B cells via transcriptomics at single-cell resolution.
Neuroregulation Signal
Detects changes in methylation, chromatin structure, & identifies vulnerable neuronal populations using transcriptomics & epigenomics at single-cell and spatial resolution.
Precision DNA Signal
Catalogs genomic rearrangements, assembles uncharacterized regions, and classifies cellular targets via long read DNA sequencing.
Multi-level RNA Signal
Detects full-length RNA isoforms and resolves SVs via long read RNA sequencing.
Immunogenomic Signal
Maps chromatin accessibility changes and epigenetic features of memory immune cells at single-cell resolution.
Neuroimmune Signal
Establishes disease-associated neural cell populations and maps immune cell infiltration in the brain via spatial transcriptomics & epigenomics.
Pathogen Signal
Determines resistance genes, resolves complex genomes, and detects bacterial epigenetic regulation via long read DNA and methylation profiling.
Proven Impact
Understanding genetic variation in young onset Parkinson’s disease
We partnered with Denali Therapeutics on an extensive genetic study of young-on-set Parkinson’s disease (YOPD) that identified novel drug targets. As an active collaborator along with Parkinson Research Alliance of India (PRAI), we initially recruited 100 YOPD patients, collected their samples and processed them. We generated whole genome data, performed diagnostic testing, and validated polygenic risk scores (PRS). This pilot study, published in Advanced Biology led to an expanded investigation, recruiting 675 YOPD patients.
Learn More
HiTMab – Monoclonal Antibody Discovery Platform
Learn how Signios Bio’s HiTMab platform accelerates monoclonal antibody discovery using single-cell BCR sequencing, enabling the identification of multiple antigen-specific B cells and delivering validated antibodies in a fraction of the time compared to traditional hybridoma methods.
Resources
April 2025
|
Services Brochure
Precision NGS data, fast turnaround, insightful bioinformatics: complete solutions for every sample type
April 2025
|
Services Brochure
Unlocking biological insights with Signios Bio’s advanced multiomics solutions
November 2024
|
Blog Post
Lung Cancer: Molecular Insights and Emerging Therapeutic Approaches